Current therapeutic approaches to primary CNS lymphoma

References

• Papers of special note have been highlighted as:
   Google Scholar
• of interest
   Google Scholar
• of considerable interest
   Google Scholar
• Olson JE, Janney CA, Rao RD et al. The continuing increase in the incidence of primary CNS nonHodgkin lymphoma: a surveillance, epidemiology and end results analysis. Cancer 95(7), 15041510 (2002).
   Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Pasini F et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 58(10), 1513 1520 (2002).
   Web of Science ®Google Scholar
• Largest published retrospective series reporting clinicopathological and therapeutic characteristics of 378 immunocompetent primary CNS lymphoma patients.
   Google Scholar
• Jellinger KA, Paulus W. Primary CNS lymphomas new pathological developments. J. Neurooncol. 24(1), 3336 (1995).
   Web of Science ®Google Scholar
• Peterson K, Gordon KB, Heinemann MH, Deangelis LM. The clinical spectrum of ocular lymphoma. Cancer 72(3), 843849 (1993).
   Web of Science ®Google Scholar
• Khan RB, Shi W, Thaler HT, Deangelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J. Neurooncol. 58(2), 175178 (2002).
   Web of Science ®Google Scholar
• Ferreri AJ, Blay JY, Reni M et al. Relevance of intraocular involvement in the management of primary CNS lymphomas. Ann. Oncol. 13(4), 531538 (2002).
   Web of Science ®Google Scholar
• Akiyama Y, Moritake K, Yamasaki T et al. The diagnostic value of 123I-IMP SPECT in non-Hodgkins lymphoma of the central nervous system. J. Nucl. Med. 41(11), 17771783 (2000).
   Google Scholar
• Shinoda J, Yano H, Murase S, Yoshimura S, Sakai N, Asano T. High 123I-IMP retention on SPECT image in primary CNS lymphoma. J. Neurooncol. 61(3), 261265 (2003).
   Google Scholar
• Roelcke U, Leenders KL. Positron emission tomography in patients with primary CNS lymphomas. J. Neurooncol. 43(3), 231236 (1999).
   Web of Science ®Google Scholar
• Gaidano G, Lo Coco F, Ye BH et al. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndromeassociated non-Hodgkins lymphoma : association with diffuse large-cell subtype. Blood 15, 397402 (1994).
   Google Scholar
• Braaten KM, Betensky R, de Leval L, Batchelor T. Bcl-6 expression predicts improved survival in patients with primary CNS lymphoma. Clin. Cancer Res. 9(3), 10631069 (2003).
   Google Scholar
• Clinicopathological study reporting bcl-6 as a favorable molecular predictor of survival.
   Google Scholar
• Ferreri AJ, Reni M, Villa E. Therapeutic management of primary CNS lymphoma: lessons from prospective trials. Ann. Oncol. 11(8), 927937 (2000).
   Google Scholar
• Ferreri AJ, Reni M, Zoldan MC, Terreni MR, Villa E. Importance of complete staging in non-Hodgkins lymphoma presenting as a cerebral mass lesion. Cancer 77(5), 827833 (1996).
   Web of Science ®Google Scholar
• ONeill BP, Dinapoli RP, Kurtin PJ, Habermann TM. Occult systemic nonHodgkins lymphoma (NHL) in patients initially diagnosed as primary CNS lymphoma (PCNSL): how much staging is enough? J. Neurooncol. 25(1), 6771 (1995).
   Google Scholar
• Deangelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary CNS lymphoma: Radiation Therapy Oncology Group Study 9310. J. Clin. Oncol. 20(24), 46434648 (2002).
   Google Scholar
• Largest Phase II trial using combination chemotherapy and radiotherapy analyzing some relevent aspects on neurotoxicity.
   Google Scholar
• Reni M, Ferreri AJ, Villa E. Second-line treatment for primary CNS lymphoma. Br. J. Cancer 79(34), 530534 (1999).
   Google Scholar
• Ferreri AJ, Blay J-Y, Reni M et al. A prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group Experience. J. Clin. Oncol. 21, 266272 (2003).
   Web of Science ®Google Scholar
• Analyses prognostic factors in primary CNS lymphoma patients describing a prognostic score able to distinguish three different risk groups of patients.
   Google Scholar
• Ponzoni M, Berger F, Chassagne C, Tinguely M, Jouvet A. Reactive perivascular T-cell infiltrate is an independent favorable prognostic factor in primary CNS lymphomas (PCNSL) in immunocompetent patients. Ann. Oncol. 13\(Suppl. 2), 264 (2002).
   Google Scholar
• Reni M, Ferreri AJ, Garancini MP, Villa E. Therapeutic management of CNS lymphoma in immunocompetent patients: results of a critical review of the literature. Ann. Oncol. 8(3), 227234 (1997).
   Web of Science ®Google Scholar
• Mead GM, Bleehen NM, Gregor A et al. A medical research council randomized trial in patients with primary cerebral non- Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy. Cancer 89(6), 13591370 (2000).
   Web of Science ®Google Scholar
• Currently the first, unique, randomized trial in primary CNS lymphoma immunocompetent patients, suggesting CHOP regimen plays no role in the treatment of these malignancies.
   Google Scholar
• Reni M, Ferreri AJ, Guha-Thakurta N et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary CNS lymphomas treated with upfront high-dose methotrexate. Int. J. Radiat. Oncol. Biol. Phys. 51(2), 419425 (2001).
   Google Scholar
• Batchelor T, Kolak G, Ciordia R, Foster S, Henson JW. High dose methotrexate for intraocular lymphoma. Clin. Cancer Res. 9(2), 711715 (2003).
   Google Scholar
• Baumann MA, Ritch PS, Hande KR, Williams GA, Topping TM, Anderson T. Treatment of intraocular lymphoma with high-dose Ara-C. Cancer 57(7), 12731275 (1986).
   Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K et al. results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Clin. Oncol. 19(3), 742749 (2001).
   Google Scholar
• Largest series of refractory or relapsed primary CNS lymphoma patients treated with intensive chemotherapy followed by peripheral blood stem cell transplantation.
   Google Scholar
• Smith JR, Rosenbaum JT, Wilson DJ et al. Role of intravitreal methotrexate in the management of primary CNS lymphoma with ocular involvement. Ophthalmology 109(9), 17091716 (2002).
   Web of Science ®Google Scholar
• Shapiro WR, Voorhies RM, Hiesiger EM, Sher PB, Basler GA, Lipschutz LE. Pharmacokinetics of tumor cell exposure to [14C] methotrexate after intracarotid administration without and with hyperosmotic opening of the blood brain and bloodtumor barriers in rat brain tumors: a quantitative autoradiographic study. Cancer Res. 48(3), 694701 (1988).
   Google Scholar
• Bessell EM, Lopez-Guillermo A, Villa S et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/ BVAM regimen followed by two different radiotherapy treatments. J. Clin. Oncol. 20(1), 231236 (2002).
   Google Scholar
• Glass J, Shustik C, Hochberg FH, Cher L, Gruber ML. Therapy of primary CNS lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine and dexamethasone (MCHOD). J. Neurooncol. 30(3), 257265 (1996).
   Google Scholar
• Dent S, Eapen L, Girard A, Hugenholtz H, DaSilva V, Stewart DJ. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. J. Neurooncol. 28(1), 2530 (1996).
   Web of Science ®Google Scholar
• Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary CNS lymphoma: response to therapy and quality of life of patients. J. Neurooncol. 43(3), 259268 (1999).
   Google Scholar
• Ng S, Rosenthal MA, Ashley D, Cher L. High-dose methotrexate for primary CNS lymphoma in the elderly. Neurooncol. 2(1), 4044 (2000).
   Google Scholar
• Hiraga S, Arita N, Ohnishi T et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary CNS lymphomas. J. Neurosurg. 91(2), 221230 (1999).
   Web of Science ®Google Scholar
• Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N. Engl. J. Med. 293(4), 161166 (1975).
   Google Scholar
• Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary CNS lymphoma: long-term outcome. J. Neurosurg. 81(2), 188195 (1994).
   Web of Science ®Google Scholar
• Ferreri AJ, Reni M, DellOro S et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary CNS lymphoma in immunocompetent patients. Oncology 60(2), 134140 (2001).
   Web of Science ®Google Scholar
• Nelson DF. Radiotherapy in the treatment of primary CNS lymphoma (PCNSL). J. Neuro-oncol. 43(3), 241247 (1999).
   Web of Science ®Google Scholar
• Deangelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 10(4), 635643 (1992).
   Google Scholar
• Blay JY, Bouhour D, Carrie C et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral nonHodgkins lymphoma of patients with no known cause of immunosuppression. Blood 86(8), 2922 2929 (1995).
   Google Scholar
• Abrey LE, Deangelis LM, Yahalom J. Longterm survival in primary CNS lymphoma. J. Clin. Oncol. 16(3), 859863 (1998).
   Google Scholar
• Camilleri-Broet S, Martin A, A M et al. Primary CNS Lymphomas in 72 Immunocompetent Patients, Pathologic findings and clinical correlations. Am. J. Clin. Pathol. 110, 607612 (1998).
   Google Scholar
• Sandor V, Stark-Vancs V, Pearson D et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J. Clin. Oncol. 16(9), 30003006 (1998).
   Google Scholar
• Batchelor T, Carson K, ONeill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 9607. J. Clin. Oncol. 21(6), 10441049 (2003).
   Google Scholar
• Phase II trial enhancing the possibility of treating primary CNS lymphoma patients with exclusive chemotherapy deferring radiotherapy.
   Google Scholar
• Herrlinger U, Schabet M, Brugger W et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary CNS lymphoma. Ann. Neurol. 51(2), 247252 (2002).
   Google Scholar
• Abrey LE, Yahalom J, Deangelis LM. Treatment for primary CNS lymphoma: the next step. J. Clin. Oncol. 18(17), 3144 3150 (2000).
   Google Scholar
• Abrey L, Moskowitz C, Mason W et al. A Phase II study of intensive methotrexate and cytarabine followed by high dose beam chemotherapy with autologous stem cell transplantation (ASCT) in patients with newly diagnosed primary CNS lymphoma (PCNSL). Proc. Am. Soc. Clin. Oncol. 20, A53 (2001) (Meeting abstract).
   Google Scholar
• Interesting study evaluating the role of high-dose chemotherapy followed by autologous stem cell transplantation in patients with newly diagnosed primary CNS lymphoma.
   Google Scholar
• Illerhaus G, Marks R, Derigs G et al. Highdose- chemotherapy with autologous pbsct and hyperfractionated radiotherapy as firstline treatment for Primary CNS Lymphoma (PCNSL) update of a Multicenter Phase II Study. Onkologie 54\(Suppl. 6), 14 (2001).
   Google Scholar
• Cheng T, Forsyth P, Chaudhry A et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant. 31(8), 679685 (2003).
   Google Scholar
• Doolittle ND, Miner ME, Hall WA et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the bloodbrain barrier for the treatment of patients with malignant brain tumors. Cancer 88(3), 637647 (2000).
   Web of Science ®Google Scholar
• Assesses the activity and toxicity of blood brain barrier disruption, an experimental therapy in primary CNS lymphoma.
   Google Scholar
• Kraemer DF, Fortin D, Neuwelt EA. Chemotherapeutic dose intensification for treatment of malignant brain tumors: Recent developments and future directions. Curr. Neurol. Neurosci. Rep. 2, 216224 (2002).
   Google Scholar
• Tyson RM, Siegal T, Doolittle ND, Lacy C, Kraemer DF, Neuwelt EA. Current status and future of relapsed primary CNS lymphoma (PCNSL). Leuk. Lymphoma (In Press) (2003).
   Google Scholar
• OBrien P, Roos D, Pratt G et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J. Clin. Oncol. 18(3), 519526 (2000).
   Google Scholar
• Deangelis LM. Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J. Neurooncol. 43(3), 249257 (1999).
   Web of Science ®Google Scholar
• Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch. Ophthalmol. 115(9), 11521156 (1997).
   Google Scholar
• Sarazin M, Ameri A, Monjour A, Nibio A, Poisson M, Delattre JY. Primary CNS lymphoma: treatment with chemotherapy and radiotherapy. Eur. J. Cancer 31A(12), 20032007 (1995).
   Google Scholar
• Shibamoto Y, Tsutsui K, Dodo Y, Yamabe H, Shima N, Abe M. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristinedoxorubicin cyclophosphamideprednisolone chemotherapy. Cancer 65(9), 19071912 (1990).
   Web of Science ®Google Scholar
• Korfel A, Fischer M, Thiel E. Response of relapsed or refractory primary CNS lymphoma (PCNSL) to topotecan. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 22 (2003).
   Google Scholar
• Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101(2), 466468 (2003).
   Web of Science ®Google Scholar
• Reni M, Ferreri AJ, Landoni C, Villa E. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J. Nat. Cancer Inst. 92(7), 575576 (2000).
   Google Scholar
• Reni M, Ferreri AJ, Perry J et al. Salvage temozolomide (TMZ) in primary brain lymphomas (PBL): a Phase II trial. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 22, 2296 (2003).
   Google Scholar
• First phase II trial assessing activity and tolerance of temozolomide as salvage therapy in primary CNS lymphoma patients.
   Google Scholar
• Varadi G, Or R, Kapelushnik J et al. Graftversus- lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary CNS lymphoma. Leuk. Lymphoma. 34(12), 185190 (1999).
   Google Scholar
• Hoang-Xuan K, Delattre JY. Ongoing protocols for nonAIDS primary CNS lymphoma. J. Neurooncol. 43(3), 287291 (1999).
   Google Scholar
• Hochman J, Assaf N, Deckert-Schluter M, Wiestler OD, Peer J. Entry routes of malignant lymphoma into the brain and eyes in a mouse model. Cancer Res. 61(13), 52425247 (2001).
   Google Scholar
• Fine HA. Primary CNS lymphoma: time to ask the question. J. Clin. Oncol. 20(24), 46154617 (2002).
   Google Scholar
• Ferreri AJM, Batchelor T, Zucca E, Armitage JO, Cavalli F. International collaborative group against primary CNS lymphomas. J. Clin. Oncol. 21(8), 1649 1650 (2003).
   Google Scholar
• Freilich RJ, Delattre JY, Monjour A, Deangelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46(2), 435439 (1996).
   Web of Science ®Google Scholar
• Schlegel U, Pels H, Glasmacher A et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J. Neurol. Neurosurg. Psychiatry 71(1), 118122 (2001).
   Google Scholar
• Cheng AL, Yeh KH, Uen WC, Hung RL, Liu MY, Wang CH. Systemic chemotherapy alone for patients with nonacquired immunodeficiency syndromerelated CNS lymphoma: a pilot study of the BOMES protocol. Cancer 82(10), 1946 1951 (1998).
   Google Scholar
• Borgognone M. SRRR. Salvage radiotherapy for immunocompetent primary nonHodgkins CNS lymphomas: an Italian study. J. Neurooncol. 2\(Suppl. 1), S46 (2000).
   Google Scholar
• Herrlinger U, Brugger W, Bamberg M, Kuker W, Dichgans J, Weller M. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54(8), 1707 1708 (2000).
   Web of Science ®Google Scholar
• Deangelis LM. Primary CNS lymphoma. PPO Updates 6(11), 113 (1992).
   Google Scholar